“…Investigation on a larger scale is necessary to address the susceptibility of ABO blood group and COVID-19 infection severity in a multiracial population to address racial disparities. [Figure: see text] DISCLOSURES: No relevant conflicts of interest to declare.…”
Enlace del recurso
Enlace del recurso

“…Finally, clinical care teams are recommended to enhance access to telehealth services and provide additional community resources to improve access to care. [Figure: see text] DISCLOSURES: Fields:Imara Inc.: Consultancy. …”
Enlace del recurso
Enlace del recurso

“…Additionally, the one positive sample from a COVID-19 unit emphasizes the need for physical separation of patients with SARS-CoV-2. [Figure: see text] DISCLOSURES: Evens:Research To Practice: Honoraria, Speakers Bureau; Merck: Consultancy, Honoraria, Research Funding; Pharmacyclics: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; MorphoSys: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria, Research Funding; Epizyme: Consultancy, Honoraria, Research Funding; Mylteni: Consultancy, Honoraria.…”
Enlace del recurso
Enlace del recurso

“…One Center Urban Experience, Detroit, MI, USA.Hemoglobin, 2020: p. 1-6. [Figure: see text] DISCLOSURES: Gregoski:National Institutes of Health under Grant Number UL1 TR001450:Current Employment.…”
Enlace del recurso
Enlace del recurso

“…This study was performed according to protocol NP-4000 (Comitato Etico Provinciale), and supported by Regione Lombardia and by the Division of Intramural Research, NIAID. [Figure: see text] DISCLOSURES: Imberti:Biogen: Honoraria; Genzyme-Sanofi: Honoraria; Meck-Serono: Honoraria; Novartis: Honoraria; Biogen: Other: Advisory board; FISM (Fondazione Italiana Sclerosi Multipla): Research Funding; Regione Lombardia: Research Funding. …”
Enlace del recurso
Enlace del recurso

“…In addition, impact on patient outcomes (such as need for return visits or bleeds) should also be evaluated. [Figure: see text] DISCLOSURES: Thornburg:Bluebird Bio: Consultancy; Biomarin: Consultancy, Speakers Bureau; Genentech: Speakers Bureau; NovoNordisk: Research Funding; Sanofi Genzyme: Consultancy, Other: Data Safety Monitoring Board, Research Funding; Spark Therapeutics: Consultancy; Ironwood Pharmaceuticals: Consultancy, Other: Data Safety Monitoring Board; National Hemophilia Foundation: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bayer Pharmaceuticals: Research Funding; American Thrombosis and Hemostasis Network: Research Funding.…”
Enlace del recurso
Enlace del recurso

“…No significant differences were observed by virus subtype or lineage. Figure 1. Declines in influenza VE over time from 2015-2016 through 2019-2020, overall (a) and by age group (b: ≤ 8 years; c: 9-17 years) [Image: see text] CONCLUSION: We observed minimal intra-season declines in VE against influenza-associated hospitalization in U.S. children. …”
Enlace del recurso
Enlace del recurso

“…Also, greater reductions from baseline viral load were shown in regdanvimab groups (Figure 1). The safety results confirmed that the regdanvimab was safe and well-tolerated. …”
Enlace del recurso
Enlace del recurso

“…Continued collection and analysis of real-world data is needed to further understand the effect of crizanlizumab therapy on utilization of acute medical care. [Figure: see text] DISCLOSURES: Jain:  DOVA: Other: advisory board; Sanofi: Other: advisory board; Argenx: Other: advisory board; Novartis: Speakers Bureau; GBT: Speakers Bureau.…”
Enlace del recurso
Enlace del recurso

“…Anti-CD20 monoclonal antibodies seem to have a smaller effect on mortality, with obinutuzumab increasing the risk of prolonged disease, but not of death, in comparison to rituximab. [Figure: see text] DISCLOSURES: Aurer:  takeda: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Swixx/BMS: Honoraria; Teva/Pilva: Honoraria; Abbvie: Consultancy, Honoraria; sanofi genzyme: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Eusapharma: Consultancy, Honoraria. …”
Enlace del recurso
Enlace del recurso

“…We did not report bleeding rates in AC groups in our study and this can be a possible reason for no mortality benefit among higher dose AC groups. [Figure: see text] DISCLOSURES: No relevant conflicts of interest to declare.…”
Enlace del recurso
Enlace del recurso

“…Care must be taken moving forward that actions to cope with the pandemic or modernize health care serve all patients. [Figure: see text] DISCLOSURES: Neuberg:  Pharmacyclics: Research Funding; Madrigal Pharmaceuticals: Other: Stock ownership. …”
Enlace del recurso
Enlace del recurso

“…Updated data will be presented at the meeting. [Figure: see text] DISCLOSURES: Sun:  Genmab: Research Funding. …”
Enlace del recurso
Enlace del recurso

“…More attention and time needs to be given to patients' education regarding vaccinations in the future. [Figure: see text] DISCLOSURES: Sacha:  Roche: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; Bristol-Myers Squibb: Honoraria, Speakers Bureau; Pfizer: Honoraria, Speakers Bureau; Angelini: Honoraria, Speakers Bureau.…”
Enlace del recurso
Enlace del recurso

“…Journal Of Thrombosis And Haemostasis, 3(4), Pp.692-694. [Figure: see text] DISCLOSURES: No relevant conflicts of interest to declare.…”
Enlace del recurso
Enlace del recurso

“…These studies will help to define optimal strategies for immunization in patients receiving BCT. [Figure: see text] DISCLOSURES: Torka:  TG Therapeutics: Membership on an entity's Board of Directors or advisory committees. …”
Enlace del recurso
Enlace del recurso

“…Higher sTM and Ba levels indicated worse clinical outcomes in children, but larger studies are needed to confirm our findings. [Figure: see text] DISCLOSURES: Sartain:  Alexon Pharamaceuticals: Membership on an entity's Board of Directors or advisory committees.…”
Enlace del recurso
Enlace del recurso

“…This finding can suggest that despite the concern for morbidity and mortality of sickle cell patients, their diligence and awareness to stay home during the pandemic has proven crucial in reducing morbidity and mortality and the option of virtual visits for healthcare delivery was key and should be utilized further in sickle cell care. [Figure: see text] DISCLOSURES: No relevant conflicts of interest to declare.…”
Enlace del recurso
Enlace del recurso

“…Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report, Chest, Volume 158, Issue 3, 2020, Pages 1143-1163, ISSN 0012-3692. [Figure: see text] DISCLOSURES: No relevant conflicts of interest to declare.…”
Enlace del recurso
Enlace del recurso

“…Overall, the hematologic monitoring of SARS-CoV-2 vaccine adopted in our survey appears appropriate to early detect and manage AIC reactivation, ensuring a safe vaccination campaign in this patient population. [Figure: see text] DISCLOSURES: Fattizzo:  Annexon: Consultancy; Alexion: Speakers Bureau; Kira: Speakers Bureau; Momenta: Honoraria, Speakers Bureau; Novartis: Speakers Bureau; Apellis: Speakers Bureau; Amgen: Honoraria, Speakers Bureau. …”
Enlace del recurso
Enlace del recurso